Guardant Health (MEX:GH) Return-on-Tangible-Equity: 0.00% (As of Mar. 2026)


MEX:GH Guardant Health Inc MEX:GH
13 GF Score
Price MXN2,590.00
GF Value MXN933.47
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guardant Health Return-on-Tangible-Equity?

Guardant Health MEX:GH 13 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates MEX:GH with a GF Score™ of 13/100 and a GF Value™ of MXN933.47 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Guardant Health ranks worse than 515463.4% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Guardant Health's annualized net income for the quarter that ended in Mar. 2026 was MXN-8,084 Mil. Guardant Health's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN-4,382 Mil. Therefore, Guardant Health's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for Guardant Health's Return-on-Tangible-Equity or its related term are showing as below:

MEX:GH's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -0.405
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Guardant Health  (MEX:GH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Guardant Health Return-on-Tangible-Equity Related Terms


Guardant Health Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Guardant Health's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health Return-on-Tangible-Equity Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.44 -185.58 -483.59 0.00 0.00

Guardant Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:GH vs LH, DGX, MEDP: Return-on-Tangible-Equity Comparison

For the Diagnostics & Research subindustry, Guardant Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Guardant Health's Return-on-Tangible-Equity falls into.


MEX:GH
13GF Score
Guardant Health Inc MEX:GH
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guardant Health Return-on-Tangible-Equity Calculation

Guardant Health's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-7495.359/( (-3122.036+-3645.884 )/ 2 )
=-7495.359/-3383.96
=N/A %

Guardant Health's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-8084.06/( (-3645.884+-5118.997)/ 2 )
=-8084.06/-4382.4405
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Guardant Health (MEX:GH) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #999999 out of 194 companies in the Medical Diagnostics & Research industry.
Is Guardant Health's Return-on-Tangible-Equity too high?
Guardant Health's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Guardant Health ranks #999999 out of 194 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Return-on-Tangible-Equity compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #999999 out of 194 companies for Return-on-Tangible-Equity. This places Guardant Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guardant Health and its competitors. Guardant Health's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN933.47, compared to a current price of MXN2,590.00 — trading 177.5% above its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Guardant Health's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guardant Health (MEX:GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of MXN2,590.00 is trading 177.5% above its estimated GF Value™ of MXN933.47. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for MEX:GH:

  • Return-on-Tangible-Equity: 0.00%
  • GF Value™: MXN933.47 vs. price of MXN2,590.00 (177.5% above fair value)
  • GF Score™: 13/100 with 3 warning signs

No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score

Get the complete analysis for MEX:GH

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,590.00
Price
MXN933.47
GF Value